68 research outputs found

    Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression

    Get PDF
    <p>Abstract</p> <p>Background</p> <p>Pulmonary metastasis continues to be the most common cause of death in osteosarcoma. Indeed, the 5-year survival for newly diagnosed osteosarcoma patients has not significantly changed in over 20 years. Further understanding of the mechanisms of metastasis and resistance for this aggressive pediatric cancer is necessary. Pet dogs naturally develop osteosarcoma providing a novel opportunity to model metastasis development and progression. Given the accelerated biology of canine osteosarcoma, we hypothesized that a direct comparison of canine and pediatric osteosarcoma expression profiles may help identify novel metastasis-associated tumor targets that have been missed through the study of the human cancer alone.</p> <p>Results</p> <p>Using parallel oligonucleotide array platforms, shared orthologues between species were identified and normalized. The osteosarcoma expression signatures could not distinguish the canine and human diseases by hierarchical clustering. Cross-species target mining identified two genes, interleukin-8 (<it>IL-8</it>) and solute carrier family 1 (glial high affinity glutamate transporter), member 3 (<it>SLC1A3</it>), which were uniformly expressed in dog but not in all pediatric osteosarcoma patient samples. Expression of these genes in an independent population of pediatric osteosarcoma patients was associated with poor outcome (p = 0.020 and p = 0.026, respectively). Validation of <it>IL-8 </it>and <it>SLC1A3 </it>protein expression in pediatric osteosarcoma tissues further supported the potential value of these novel targets. Ongoing evaluation will validate the biological significance of these targets and their associated pathways.</p> <p>Conclusions</p> <p>Collectively, these data support the strong similarities between human and canine osteosarcoma and underline the opportunities provided by a comparative oncology approach as a means to improve our understanding of cancer biology and therapies.</p

    DNA repair deficiency biomarkers and the 70-gene ultra-high risk signature as predictors of veliparib/carboplatin response in the I-SPY 2 breast cancer trial.

    Get PDF
    Veliparib combined with carboplatin (VC) was an experimental regimen evaluated in the biomarker-rich neoadjuvant I-SPY 2 trial for breast cancer. VC showed improved efficacy in the triple negative signature. However, not all triple negative patients achieved pathologic complete response and some HR+HER2- patients responded. Pre-specified analysis of five DNA repair deficiency biomarkers (BRCA1/2 germline mutation; PARPi-7, BRCA1ness, and CIN70 expression signatures; and PARP1 protein) was performed on 116 HER2- patients (VC: 72 and concurrent controls: 44). We also evaluated the 70-gene ultra-high risk signature (MP1/2), one of the biomarkers used to define subtype in the trial. We used logistic modeling to assess biomarker performance. Successful biomarkers were combined using a simple voting scheme to refine the 'predicted sensitive' group and Bayesian modeling used to estimate the pathologic complete response rates. BRCA1/2 germline mutation status associated with VC response, but its low prevalence precluded further evaluation. PARPi-7, BRCA1ness, and MP1/2 specifically associated with response in the VC arm but not the control arm. Neither CIN70 nor PARP1 protein specifically predicted VC response. When we combined the PARPi-7 and MP1/2 classifications, the 42% of triple negative patients who were PARPi7-high and MP2 had an estimated pCR rate of 75% in the VC arm. Only 11% of HR+/HER2- patients were PARPi7-high and MP2; but these patients were also more responsive to VC with estimated pathologic complete response rates of 41%. PARPi-7, BRCA1ness and MP1/2 signatures may help refine predictions of VC response, thereby improving patient care

    The Comparative Oncology Trials Consortium: Using Spontaneously Occurring Cancers in Dogs to Inform the Cancer Drug Development Pathway

    Get PDF
    Chand Khanna and colleagues describe the work of the Comparative Oncology Trials Consortium (COTC), which provides infrastructure and resources to integrate naturally occurring dog cancer models into the development of new human cancer drugs, devices, and imaging techniques

    Rapamycin Pharmacokinetic and Pharmacodynamic Relationships in Osteosarcoma: A Comparative Oncology Study in Dogs

    Get PDF
    Signaling through the mTOR pathway contributes to growth, progression and chemoresistance of several cancers. Accordingly, inhibitors have been developed as potentially valuable therapeutics. Their optimal development requires consideration of dose, regimen, biomarkers and a rationale for their use in combination with other agents. Using the infrastructure of the Comparative Oncology Trials Consortium many of these complex questions were asked within a relevant population of dogs with osteosarcoma to inform the development of mTOR inhibitors for future use in pediatric osteosarcoma patients.This prospective dose escalation study of a parenteral formulation of rapamycin sought to define a safe, pharmacokinetically relevant, and pharmacodynamically active dose of rapamycin in dogs with appendicular osteosarcoma. Dogs entered into dose cohorts consisting of 3 dogs/cohort. Dogs underwent a pre-treatment tumor biopsy and collection of baseline PBMC. Dogs received a single intramuscular dose of rapamycin and underwent 48-hour whole blood pharmacokinetic sampling. Additionally, daily intramuscular doses of rapamycin were administered for 7 days with blood rapamycin trough levels collected on Day 8, 9 and 15. At Day 8 post-treatment collection of tumor and PBMC were obtained. No maximally tolerated dose of rapamycin was attained through escalation to the maximal planned dose of 0.08 mg/kg (2.5 mg/30 kg dog). Pharmacokinetic analysis revealed a dose-dependent exposure. In all cohorts modulation of the mTOR pathway in tumor and PBMC (pS6RP/S6RP) was demonstrated. No change in pAKT/AKT was seen in tumor samples following rapamycin therapy.Rapamycin may be safely administered to dogs and can yield therapeutic exposures. Modulation pS6RP/S6RP in tumor tissue and PBMCs was not dependent on dose. Results from this study confirm that the dog may be included in the translational development of rapamycin and potentially other mTOR inhibitors. Ongoing studies of rapamycin in dogs will define optimal schedules for their use in cancer and evaluate the role of rapamycin use in the setting of minimal residual disease

    Prospective Molecular Profiling of Canine Cancers Provides a Clinically Relevant Comparative Model for Evaluating Personalized Medicine (PMed) Trials.

    Get PDF
    Background Molecularly-guided trials (i.e. PMed) now seek to aid clinical decision-making by matching cancer targets with therapeutic options. Progress has been hampered by the lack of cancer models that account for individual-to-individual heterogeneity within and across cancer types. Naturally occurring cancers in pet animals are heterogeneous and thus provide an opportunity to answer questions about these PMed strategies and optimize translation to human patients. In order to realize this opportunity, it is now necessary to demonstrate the feasibility of conducting molecularly-guided analysis of tumors from dogs with naturally occurring cancer in a clinically relevant setting. Methodology A proof-of-concept study was conducted by the Comparative Oncology Trials Consortium (COTC) to determine if tumor collection, prospective molecular profiling, and PMed report generation within 1 week was feasible in dogs. Thirty-one dogs with cancers of varying histologies were enrolled. Twenty-four of 31 samples (77%) successfully met all predefined QA/QC criteria and were analyzed via Affymetrix gene expression profiling. A subsequent bioinformatics workflow transformed genomic data into a personalized drug report. Average turnaround from biopsy to report generation was 116 hours (4.8 days). Unsupervised clustering of canine tumor expression data clustered by cancer type, but supervised clustering of tumors based on the personalized drug report clustered by drug class rather than cancer type. Conclusions Collection and turnaround of high quality canine tumor samples, centralized pathology, analyte generation, array hybridization, and bioinformatic analyses matching gene expression to therapeutic options is achievable in a practical clinical window (\u3c1 \u3eweek). Clustering data show robust signatures by cancer type but also showed patient-to-patient heterogeneity in drug predictions. This lends further support to the inclusion of a heterogeneous population of dogs with cancer into the preclinical modeling of personalized medicine. Future comparative oncology studies optimizing the delivery of PMed strategies may aid cancer drug development

    Launching a Novel Preclinical Infrastructure: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNFΞ± to Cancer Vasculature

    Get PDF
    Background: Under the direction and sponsorship of the National Cancer Institute, we report on the first pre-clinical trial of the Comparative Oncology Trials Consortium (COTC). The COTC is a novel infrastructure to integrate cancers that naturally develop in pet dogs into the development path of new human drugs. Trials are designed to address questions challenging in conventional preclinical models and early phase human trials. Large animal spontaneous cancer models can be a valuable addition to successful studies of cancer biology and novel therapeutic drug, imaging and device development. Methodology/Principal Findings: Through this established infrastructure, the first trial of the COTC (COTC001) evaluated a targeted AAV-phage vector delivering tumor necrosis factor (RGD-A-TNF) to Ξ±V integrins on tumor endothelium. Trial progress and data was reviewed contemporaneously using a web-enabled electronic reporting system developed for the consortium. Dose-escalation in cohorts of 3 dogs (n = 24) determined an optimal safe dose (5 x 1012 transducing units intravenous) of RGD-A-TNF. This demonstrated selective targeting of tumor-associated vasculature and sparing of normal tissues assessed via serial biopsy of both tumor and normal tissue. Repetitive dosing in a cohort of 14 dogs, at the defined optimal dose, was well tolerated and led to objective tumor regression in two dogs (14%), stable disease in six (43%), and disease progression in six (43%) via Response Evaluation Criteria in Solid Tumors (RECIST). Conclusions/Significance: The first study of the COTC has demonstrated the utility and efficiency of the established infrastructure to inform the development of new cancer drugs within large animal naturally occurring cancer models. The preclinical evaluation of RGD-A-TNF within this network provided valuable and necessary data to complete the design of first-in-man studies

    Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

    Get PDF

    ΠœΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½Ρ‹ΠΉ ΠΌΡƒΠ·Ρ‹ΠΊΠ°Π»ΡŒΠ½Ρ‹ΠΉ конкурс Π² Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° страны провСдСния (Π½Π° ΠΏΡ€ΠΈΠΌΠ΅Ρ€Π΅ ЕвровидСния 2017)

    Get PDF
    Аннотация выпускной ΠΊΠ²Π°Π»ΠΈΡ„ΠΈΠΊΠ°Ρ†ΠΈΠΎΠ½Π½ΠΎΠΉ Ρ€Π°Π±ΠΎΡ‚Ρ‹ ΠžΡ€Π»ΠΎΠ² Никита Π‘Π΅Ρ€Π³Π΅Π΅Π²ΠΈΡ‡ Β«ΠœΠ•Π–Π”Π£ΠΠΠ ΠžΠ”ΠΠ«Π™ ΠœΠ£Π—Π«ΠšΠΠ›Π¬ΠΠ«Π™ КОНКУРБ Π’ Π€ΠžΠ ΠœΠ˜Π ΠžΠ’ΠΠΠ˜Π˜ Π˜ΠœΠ˜Π”Π–Π БВРАНЫ ΠŸΠ ΠžΠ’Π•Π”Π•ΠΠ˜Π― (НА ΠŸΠ Π˜ΠœΠ•Π Π• Π•Π’Π ΠžΠ’Π˜Π”Π•ΠΠ˜Π―-2017)Β» Н. Ρ€ΡƒΠΊ. - Π‘Ρ‹ΠΊΠΎΠ²Π° Π•Π»Π΅Π½Π° Π’Π»Π°Π΄ΠΈΠΌΠΈΡ€ΠΎΠ²Π½Π°, Π΄ΠΎΠΊΡ‚ΠΎΡ€ филологичСских Π½Π°ΡƒΠΊ, Π΄ΠΎΡ†Π΅Π½Ρ‚ ΠšΠ°Ρ„Π΅Π΄Ρ€Π° связСй с ΠΎΠ±Ρ‰Π΅ΡΡ‚Π²Π΅Π½Π½ΠΎΡΡ‚ΡŒΡŽ ΠžΡ‡Π½Π°Ρ Ρ„ΠΎΡ€ΠΌΠ° обучСния ΠΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ: ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½Ρ‹ΠΉ ΠΌΡƒΠ·Ρ‹ΠΊΠ°Π»ΡŒΠ½Ρ‹ΠΉ конкурс Π•Π²Ρ€ΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊ самоС ΠΌΠ°ΡΡˆΡ‚Π°Π±Π½ΠΎΠ΅ рСгулярноС высокотСхнологичноС Ρ‚Π΅Π»Π΅Π²ΠΈΠ·ΠΈΠΎΠ½Π½ΠΎΠ΅ ΠΈ ΠΌΠ΅Π΄ΠΈΠ°-событиС, ΠΊΠΎΡ‚ΠΎΡ€ΠΎΠ΅ . Π• Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΠΎ Π°ΠΊΡ†Π΅Π½Ρ‚ΠΈΡ€ΡƒΠ΅Ρ‚ Π²Π½ΠΈΠΌΠ°Π½ΠΈΠ΅ Π°ΡƒΠ΄ΠΈΡ‚ΠΎΡ€ΠΈΠΈ Π½Π° Π½Π°Ρ†ΠΈΠΎΠ½Π°Π»ΡŒΠ½ΠΎ-ΠΊΡƒΠ»ΡŒΡ‚ΡƒΡ€Π½Ρ‹Ρ… особСнностях страны-ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ‚ΠΎΡ€Π° конкурса, Ρ„ΠΎΡ€ΠΌΠΈΡ€ΡƒΠ΅Ρ‚ Π·Π½Π°Ρ‡ΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹Π΅ туристичСскиС ΠΏΠΎΡ‚ΠΎΠΊΠΈ ΠΈ Ρ‚Π΅ΠΌ самым способствуСт Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΡŽ ΠΈΠΌΠΈΠ΄ΠΆΠ° Ρ‚Π΅Ρ€Ρ€ΠΈΡ‚ΠΎΡ€ΠΈΠΈ. Π‘ΠΎΠ»Π΅Π΅ Ρ‚ΠΎΠ³ΠΎ, ΠΏΠΎΠ±Π΅Π΄Π° страны-участницы конкурса ЕвровидСния Π·Π°Ρ‡Π°ΡΡ‚ΡƒΡŽ ΠΎΡ‚Ρ€Π°ΠΆΠ°Π΅Ρ‚ ΠΈΠ΄Π΅ΠΎΠ»ΠΎΠ³ΠΎ-политичСский Π²Π΅ΠΊΡ‚ΠΎΡ€ Π•Π²Ρ€ΠΎΠΏΡ‹ ΠΈ ΠΏΠΎ сути Π΄Π΅Π»Π° выполняСт Ρ„ΡƒΠ½ΠΊΡ†ΠΈΡŽ политичСского PR страны-побСдитСля ΠΈ страны-хозяйки мСроприятия. Π‘Π»Π΅Π΄ΠΎΠ²Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎ Π°Π½Π°Π»ΠΈΠ· ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΡƒΠ΅ΠΌΡ‹Ρ… Π½Π° мСроприятии ΠΊΠΎΠΌΠΌΡƒΠ½ΠΈΠΊΠ°Ρ‚ΠΈΠ²Π½Ρ‹Ρ… Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ являСтся Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½Ρ‹ΠΌ ΠΈ вострСбованным для событийного ΠΈ ΡƒΡΡ‚Ρ€ΠΎΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ PR ΠžΠ±ΡŠΠ΅ΠΊΡ‚ исслСдования: ΠΊΠΎΠΌΠΌΡƒΠ½ΠΈΠΊΠ°Ρ†ΠΈΠΎΠ½Π½Ρ‹Π΅ активности ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΌΡƒΠ·Ρ‹ΠΊΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ конкурса (Π½Π° ΠΏΡ€ΠΈΠΌΠ΅Ρ€Π΅ ЕвровидСния Π² КиСвС Π² 2017 Π³.). ΠŸΡ€Π΅Π΄ΠΌΠ΅Ρ‚ исслСдования: функция статусного PR-мСроприятия Π² Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° страны. ЦСль исслСдования: Π΄ΠΎΠΊΠ°Π·Π°Ρ‚ΡŒ, Ρ‡Ρ‚ΠΎ ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½Ρ‹ΠΉ ΠΌΡƒΠ·Ρ‹ΠΊΠ°Π»ΡŒΠ½Ρ‹ΠΉ конкурс Π•Π²Ρ€ΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ способствуСт Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΡŽ ΠΈΠΌΠΈΠ΄ΠΆΠ° страны провСдСния. Π—Π°Π΄Π°Ρ‡ΠΈ исслСдования: Ρ€Π°Π·Ρ€Π°Π±ΠΎΡ‚Π°Ρ‚ΡŒ тСрминологичСский Π°ΠΏΠΏΠ°Ρ€Π°Ρ‚ исслСдования Π½Π° основС Π½Π°ΡƒΡ‡Π½ΠΎΠΉ Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹ ΠΏΠΎ ΠΈΠΌΠΈΠ΄ΠΆΠΌΠ΅ΠΉΠΊΠΈΠ½Π³Ρƒ, Π±Ρ€Π΅Π½Π΄ΠΈΠ½Π³Ρƒ ΠΈ ΠΈΠ²Π΅Π½Ρ‚-ΠΌΠ΅Π½Π΅Π΄ΠΆΠΌΠ΅Π½Ρ‚Ρƒ; ΠΎΠΏΡ€Π΅Π΄Π΅Π»ΠΈΡ‚ΡŒ Π°ΠΊΡ‚ΡƒΠ°Π»ΡŒΠ½Ρ‹Π΅ ΠΊΠΎΠΌΠΌΡƒΠ½ΠΈΠΊΠ°Ρ†ΠΈΠΎΠ½Π½Ρ‹Π΅ Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΈ, примСняСмыС Π² Ρ€Π°ΠΌΠΊΠ°Ρ… ΡΠΏΠ΅Ρ†ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… событий для формирования ΠΈΠΌΠΈΠ΄ΠΆΠ° страны; ΠΎΠΏΠΈΡΠ°Ρ‚ΡŒ Ρ€ΠΎΠ»ΡŒ ЕвропСйского Π’Π΅Ρ‰Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Боюза ΠΊΠ°ΠΊ ΠΎΡ€Π³Π°Π½ΠΈΠ·Π°Ρ‚ΠΎΡ€Π° ЕвровидСния Π² Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° страны провСдСния конкурса; ΠΎΡ†Π΅Π½ΠΈΡ‚ΡŒ ΡΡ„Ρ„Π΅ΠΊΡ‚ΠΈΠ²Π½ΠΎΡΡ‚ΡŒ Ρ€Π΅Π°Π»ΠΈΠ·ΠΎΠ²Π°Π½Π½Ρ‹Ρ… ΠΊΠΎΠΌΠΌΡƒΠ½ΠΈΠΊΠ°Ρ‚ΠΈΠ²Π½Ρ‹Ρ… Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ формирования ΠΈΠΌΠΈΠ΄ΠΆΠ° страны Π² Ρ€Π°ΠΌΠΊΠ°Ρ… ЕвровидСния; Π΄Π°Ρ‚ΡŒ Ρ€Π΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°Ρ†ΠΈΠΈ ΠΏΠΎ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΡŽ ΠΈΠΌΠΈΠ΄ΠΆΠ° страны с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ЕвровидСния. ВСорСтичСская Π±Π°Π·Π°: Π½Π°ΡƒΡ‡Π½Ρ‹Π΅ Ρ‚Ρ€ΡƒΠ΄Ρ‹ Π•. Π‘Ρ‹ΠΊΠΎΠ²ΠΎΠΉ, Π”. Π“Π°Π²Ρ€Ρ‹, А. ΠŸΠ°Π½ΠΊΡ€ΡƒΡ…ΠΈΠ½Π°, Π‘. ДТСнСса, Π•. ΠšΠ°Π²Π΅Ρ€ΠΈΠ½ΠΎΠΉ, Π£. Π₯Π°Π»ΡŒΡ†Π±Π°ΡƒΡ€Π°, Π”ΠΆ. Π“ΠΎΠ»Π΄Π±Π»Π°Ρ‚Ρ‚Π° Π° Ρ‚Π°ΠΊΠΆΠ΅ Ρ‚Ρ€ΡƒΠ΄Ρ‹ Π”. Пассмана ΠΎ ΠΌΡƒΠ·Ρ‹ΠΊΠ°Π»ΡŒΠ½ΠΎΠΌ бизнСсС, П. Π”ΠΆΠΎΡ€Π΄Π°Π½Π° ΠΎ ΠΏΡ€ΠΎΠ΄Π²ΠΈΠΆΠ΅Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° стран с ΠΏΠΎΠΌΠΎΡ‰ΡŒΡŽ ЕвровидСния ΠΈ Π΄Ρ€. ЭмпиричСская Π±Π°Π·Π°: PR-Π΄ΠΎΠΊΡƒΠΌΠ΅Π½Ρ‚Ρ‹, Ρ€Π°Π·ΠΌΠ΅Ρ‰Π΅Π½Π½Ρ‹Π΅ Π½Π° сайтС ЕвровидСния ΠΈ ЕвропСйского Π’Π΅Ρ‰Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Боюза; Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»ΡƒΡ‚ΠΎΡ€Π° ΠΌΠΈΠ»Π»ΠΈΠΎΠ½Π° статСй ΠΎΠ± Π£ΠΊΡ€Π°ΠΈΠ½Π΅ Π² СвропСйских БМИ, Ρ€Π°Π·ΠΌΠ΅Ρ‰Π΅Π½Π½Ρ‹Π΅ Π² Π±Π°Π·Π΅ ΠΏΡ€ΠΎΠ΅ΠΊΡ‚Π° ΠΌΠΎΠ½ΠΈΡ‚ΠΎΡ€ΠΈΠ½Π³Π° ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½ΠΎΠ³ΠΎ ΠΈΠΌΠΈΠ΄ΠΆΠ° Π£ΠΊΡ€Π°ΠΈΠ½Ρ‹ Β«OkoΒ»; Π΄Π°Π½Π½Ρ‹Π΅ Π±Π°Π·Ρ‹ ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»ΠΎΠ² БМИ ΠΈ ΡΠΎΡ†ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΌΠ΅Π΄ΠΈΠ° Factiva; Π΄Π°Π½Π½Ρ‹Π΅ Google.Analytics. ΠŸΡ€Π°ΠΊΡ‚ΠΈΡ‡Π΅ΡΠΊΠ°Ρ Π·Π½Π°Ρ‡ΠΈΠΌΠΎΡΡ‚ΡŒ: исслСдованиС Π΄ΠΎΠΊΠ°Π·Ρ‹Π²Π°Π΅Ρ‚, Ρ‡Ρ‚ΠΎ ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½Ρ‹ΠΉ ΠΌΡƒΠ·Ρ‹ΠΊΠ°Π»ΡŒΠ½Ρ‹ΠΉ конкурс Π•Π²Ρ€ΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ Ρ„ΠΎΡ€ΠΌΠΈΡ€ΡƒΠ΅Ρ‚ ΠΈΠΌΠΈΠ΄ΠΆ страны провСдСния нСзависимо ΠΎΡ‚ ΡƒΡΠΏΠ΅ΡˆΠ½ΠΎΡΡ‚ΠΈ использования ΠΊΠΎΠ½ΠΊΡ€Π΅Ρ‚Π½Ρ‹Ρ… Ρ‚Π΅Ρ…Π½ΠΎΠ»ΠΎΠ³ΠΈΠΉ формирования ΠΈΠΌΠΈΠ΄ΠΆΠ° страны. ВСзисы исслСдования Π±Ρ‹Π»ΠΈ Π°ΠΏΡ€ΠΎΠ±ΠΈΡ€ΠΎΠ²Π°Π½Ρ‹ Π½Π° ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½ΠΎΠΌ Π½Π°ΡƒΡ‡Π½ΠΎΠΌ Ρ„ΠΎΡ€ΡƒΠΌΠ΅ «МСдиа Π² соврСмСнном ΠΌΠΈΡ€Π΅. 57-Π΅ ΠŸΠ΅Ρ‚Π΅Ρ€Π±ΡƒΡ€Π³ΡΠΊΠΈΠ΅ чтСния», ΠΎΠΏΡƒΠ±Π»ΠΈΠΊΠΎΠ²Π°Π½Ρ‹ Π² сборникС ΠΌΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»ΠΎΠ² статСй Ρ„ΠΎΡ€ΡƒΠΌΠ° ΠΈ ΠΈΠΌΠ΅ΡŽΡ‚ статус Π½Π°ΡƒΡ‡Π½ΠΎΠΉ ΡΡ‚Π°Ρ‚ΡŒΠΈ, Ρ€Π°Π·ΠΌΠ΅Ρ‰Π΅Π½Π½ΠΎΠΉ Π² Π±Π°Π·Π΅ РИНЦ. Π‘Ρ‚Ρ€ΡƒΠΊΡ‚ΡƒΡ€Π° Ρ€Π°Π±ΠΎΡ‚Ρ‹: Π Π°Π±ΠΎΡ‚Π° состоит ΠΈΠ· ввСдСния, 3 Π³Π»Π°Π²: «функция ΡΠΏΠ΅Ρ†ΠΈΠ°Π»ΡŒΠ½ΠΎΠ³ΠΎ события Π² Ρ„ΠΎΡ€ΠΌΠΈΡ€ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠΌΠΈΠ΄ΠΆΠ° страны», Β«Π•Π²Ρ€ΠΎΠ²ΠΈΠ΄Π΅Π½ΠΈΠ΅ ΠΊΠ°ΠΊ ΡΠΏΠ΅Ρ†ΠΈΠ°Π»ΡŒΠ½ΠΎΠ΅ событиС ЕвропСйского Π’Π΅Ρ‰Π°Ρ‚Π΅Π»ΡŒΠ½ΠΎΠ³ΠΎ Боюза» ΠΈ Β«ΠΊΠΎΠΌΠΌΡƒΠ½ΠΈΠΊΠ°Ρ†ΠΈΠΎΠ½Π½Ρ‹ΠΉ ΠΏΠΎΡ‚Π΅Π½Ρ†ΠΈΠ°Π» ЕвровидСния ΠΊΠ°ΠΊ ΠΏΠ»ΠΎΡ‰Π°Π΄ΠΊΠΈ для формирования ΠΈΠΌΠΈΠ΄ΠΆΠ° страны», Π·Π°ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΡ, списка использованной Π»ΠΈΡ‚Π΅Ρ€Π°Ρ‚ΡƒΡ€Ρ‹ ΠΈΠ· 67 ΠΏΠΎΠ·ΠΈΡ†ΠΈΠΉ ΠΈ 12 ΠΏΡ€ΠΈΠ»ΠΎΠΆΠ΅Π½ΠΈΠΉ. ΠžΠ±Ρ‰ΠΈΠΉ объСм 76 страниц.Abstract of graduating qualification thesis Mikita Arlou INTERNATIONAL MUSIC CONTEST IN HOST COUNTRY IMAGE FORMATION (ON THE EXAMPLE OF EUROVISION 2017) Supervisor associate professor Elena Bykova, doctor of philology Department of PR in business full-time study Relevance: the international music contest Eurovision as the most wide scale regular high tech TV and Media event which annually emphasizes audience attention on national cultural features of the host country, forms tourist flows which have huge influence on territorial image formation. Besides the win of a participating in the Eurovision country often shows the ideological and political European vector and in fact serves as political PR of the winning or host country. Consequently the analysis of applied communication technologies is relevant and in-demand for event PR. Research object: communication activities of international music contest (on the example of Eurovision in Kyiv in 2017). Research subject: function of status PR event in country image formation. The aim of research: to prove that international music contest Eurovision contributes host country image formation. The tasks of research: to develop research terminology based on scientific literature on image making, branding and event management; to define actual communication technologies applied in special PR events on country image formation; to describe European Broadcasting Union role in host country image formation; to appreciate effectiveness of applied communication technologies on host country image formation in Eurovision; to give recommendations for host country image formation with the help of Eurovision. Theoretical base: scientific works written by E. Bykova, D. Gavra, A. Pankrukhin, B. Jenes, E. Kaverina, U. Halcbaur, J. Goldblatt and D. PassmanΒ΄s works on music business and P. Jordan on county image building with the help of Eurovision, etc. The empirical base: PR documents from official Eurovision and European Broadcasting Union websites; more than 1.5 million articles on Ukraine in European media stored in the base of international Ukrainian image monitoring project Oko; content of the mass media and social media base Factiva; Google.Analytics data. Practical significance: the research proves that international music contest Eurovision is relevant for the host country image formation independently of the success level of applied country image formation communication technologies. Approbation: General positions of current thesis were aprobated on international scientific forum Media in modern world and were published at the collection of articles of the forum and have the status of a scientific article posted in the RINC database. Thesis structure: Research consists of introduction, 3 chapters: Special event function in country image formation, Eurovision as EBU special event and communication potential of Eurovision as a platform for image formation; conclusion, literature list from 67 positions and 12 attachments. The total volume is 76 pages

    A compendium of canine normal tissue gene expression.

    Get PDF
    BACKGROUND: Our understanding of disease is increasingly informed by changes in gene expression between normal and abnormal tissues. The release of the canine genome sequence in 2005 provided an opportunity to better understand human health and disease using the dog as clinically relevant model. Accordingly, we now present the first genome-wide, canine normal tissue gene expression compendium with corresponding human cross-species analysis. METHODOLOGY/PRINCIPAL FINDINGS: The Affymetrix platform was utilized to catalogue gene expression signatures of 10 normal canine tissues including: liver, kidney, heart, lung, cerebrum, lymph node, spleen, jejunum, pancreas and skeletal muscle. The quality of the database was assessed in several ways. Organ defining gene sets were identified for each tissue and functional enrichment analysis revealed themes consistent with known physio-anatomic functions for each organ. In addition, a comparison of orthologous gene expression between matched canine and human normal tissues uncovered remarkable similarity. To demonstrate the utility of this dataset, novel canine gene annotations were established based on comparative analysis of dog and human tissue selective gene expression and manual curation of canine probeset mapping. Public access, using infrastructure identical to that currently in use for human normal tissues, has been established and allows for additional comparisons across species. CONCLUSIONS/SIGNIFICANCE: These data advance our understanding of the canine genome through a comprehensive analysis of gene expression in a diverse set of tissues, contributing to improved functional annotation that has been lacking. Importantly, it will be used to inform future studies of disease in the dog as a model for human translational research and provides a novel resource to the community at large
    • …
    corecore